Denali and Biogen Discontinue Parkinson's Drug BIIB122 After Phase 2b Trial Failure
DNLI sits 42% above its 52-week low of $12.58.
Summary
Denali Therapeutics and Biogen are discontinuing their Parkinson's disease drug BIIB122 after its Phase 2b trial failed to meet efficacy endpoints, marking a major pipeline setback.
Key Events · Product Development and Regulatory · DNLI
-
Phase 2b LUMA Study Failed
The BIIB122 (DNL151) study in early-stage Parkinson's disease did not meet its primary or secondary endpoints for slowing disease progression.
-
Program Discontinuation
Biogen and Denali will discontinue further development of BIIB122 for idiopathic Parkinson's disease based on the trial results.
-
LRRK2 Variant Study Continues
Denali will independently continue the Phase 2a BEACON study of BIIB122 in carriers of a pathogenic LRRK2 variant, with data expected in H1 2027.
-
Biomarker Engagement Observed
Exploratory biomarker endpoints showed over 90% kinase inhibition of peripheral LRRK2 and a reduction in phosphorylated Rab10, indicating the drug engaged its target despite clinical failure.
Analysis · DNLI · Life Sciences
The Phase 2b LUMA study for BIIB122 in early-stage Parkinson's disease failed to meet its primary and secondary endpoints, leading Denali and Biogen to discontinue its development for idiopathic Parkinson's. This represents a significant setback for Denali's pipeline in a major neurodegenerative disease, despite the drug showing target engagement. The company will continue a separate Phase 2a study for a specific genetic variant.
At the time of this filing, DNLI was trading at $17.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $12.58 to $23.77. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.